Zymeworks Inc(NASDAQ:ZYME) 
Zymeworks Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes biotherapeutics for the treatment of cancer. The company's lead product candidates include zanidatamab, a novel bispecific antibody that is in Phase 1 and Phase 2 clinical trials for the treatment of ...
Website: http://www.zymeworks.com
Founded: 2003
Full Time Employees: 325
Sector: Healthcare
Industry: Biotechnology
The information provided in this report is taken from www.sec.gov. While we have conducted our best efforts to ensure that the parsed data is accurate, we cannot guarantee its accuracy. Please use caution and understand that any consequences of its use are your own responsibility.
Day
Week
Month
Date 2025-04-04
P
O 11.40
H 11.75
L 10.61
C 10.95
V 1,241,592
10EMA 10.95
20EMA 10.95
60EMA 10.95
120EMA 10.95
250EMA 10.95